The Latest Cardiac and Vascular News
ANDOVER, Mass., May 30, 2023 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 24, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 87,472 shares of its common stock […]
WEST CHESTER, Pa., May 31, 2023 /PRNewswire/ — VESTECK, Inc. is excited to announce the successful completion of 7 Endovascular Aortic Repair (EVAR) clinical cases with the “SUTURE-TIGHT”™ device. Professor Dainis Krievins and Dr. Bao Bui, performed the 2 most recent EVAR procedures in Riga, Latvia, suturing EVAR grafts to the aorta with the “SUTURE-TIGHT”™ catheter. […]
The data collected from the usage and experience of the medical professionals in the formative study will be used to support the Company’s anticipated milestones HINGHAM, Mass., May 31, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular surgical […]
SANTA CLARA, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today released its 2022 ESG Report highlighting accomplishments in environmental, social, and governance (ESG) across its global markets. “We are […]
The proportion of acute cerebral ischemic stroke patients with the mRS of 0-2 on day 90 post-randomization was statistically significant (p=0.002) Sovateltide is a first-in-class drug that increases blood flow, inhibits apoptosis, and induces neurovascular remodeling WILLOWBROOK, Ill., May 31, 2023 (GLOBE NEWSWIRE) — Pharmazz, Inc. (“Pharmazz” or the “Company”), […]
Once granted, this patent will provide intellectual property protection until December 2040, and may qualify for additional U.S. patent term extension beyond 2040 There are currently no FDA approved treatments for PH-HFpEF, a condition affecting more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients […]
TAMPA, Fla., May 29, 2023 /PRNewswire/ — The US FDA, on the 24th of May 2023, granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc’s Sirolimus Coated Balloon (SCB) MagicTouch PTA for the treatment of Superficial Femoral Arteries (SFA). This marks the fourth IDE approval for the Company’s Sirolimus coated balloon. The Company has already received three […]
SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform intended for patient use at home, today announced that it has entered into a Strategic Alliance Agreement (SAA) with Samsung, extending the existing SAA between LIVMOR and Samsung. HeartBeam […]
NETANYA, Israel, May 30, 2023 /PRNewswire/ — Revamp Medical, Inc., a privately held clinical-stage medical technology company committed to developing solutions for Heart Failure congestion management, today announced closing of a Series A preferred stock financing led by KCK Medtech. Major existing investors Arkin and Accelmed also participated in the financing as well as Michael […]
GENEVA, May 30, 2023 /PRNewswire/ — 12-month results from the SELUTION SFA trial have been presented at the Japan Endovascular Treatment (JET) Conference in Tokyo. The objective of this study was to assess the safety and efficacy of SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, for endovascular therapy of de novo and non-stented restenotic lesions in the […]
